# Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)

> **NCT06648512** · — · COMPLETED · sponsor: **Exscientia AI Limited** · enrollment: 91 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Acute Myeloid Leukemia (AML) Relapse

## Interventions

- **OTHER:** No Interventions

## Key facts

- **NCT ID:** NCT06648512
- **Lead sponsor:** Exscientia AI Limited
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-13
- **Primary completion:** 2025-03-07
- **Final completion:** 2025-03-07
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2025-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648512

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648512, "Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06648512. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*